All In Biotech

Drug Trial Radar · NCT00645255

Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Examine the Longer-Term Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Obese Subjects

Last checked: Nov 20, 2026Latest source record: Mar 27, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 466 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

466

Actual

Start

Sep 1998

Primary completion

Jan 2003

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Mar 27, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was designed to evaluate the long term efficacy and safety of Meridia 15 mg daily in obese subjects.

Conditions

  • Obesity
  • Weight Loss

Interventions

  • placeboDrug

    placebo one capsule daily

  • sibutramine or placeboDrug

    one capsule daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Body Weight LossTime frame: Mean Change From Baseline

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.